The microtitre succinate dehydrogenase inhibition test for chemosensitivity of human tumour cells

DOI PubMed

この論文をさがす

説明

THE succinate dehydrogenase inhibition (SDI) test is a simple, rapid and inexpensive test to determine chemosensitivity of tumour cells to anticancer drugs. It is based on the correlation of succinate dehydrogenase (EC 1.3.99.1) activity with cell viability [ 1, 21 and shares a common principle with the MTT dye assay [3]. We have developed and evaluated a microtitre test, and report our findings with this micro test compared with the SD1 test. The macro test was done as described [ 1, 21. For the micro test, the SD1 test was modified as follows: firstly, single cell suspensions were obtained by enzymatic disaggregation of solid tumours with 0.2% pronase, 0.25% collagenase and 0.1% DNase for 20 min at 37°C which gave a higher cell yield and viability compared with mechanical disaggregation used in the macro test; secondly, the formazan crystals were dissolved with dimethyl sulphoxide, giving a higher absorption peak, with a microtitre plate spectrophotometer (Easy Reader EAR340, SLT Laboinstruments, Austria). Human cancer tissues from 16 patients (Table 1) were used for both tests. We confirmed that absorbance of the formazan product was proportional to the number of tumour cells ( 103-lo5 cells per well in the micro test). To assess chemosensitivity, the micro SD1 test required 2-5 x lo4 tumour cells per well, one-

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ